Literature DB >> 19462483

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Zeynep S Teksin1, Insong J Lee, Noble N Nemieboka, Ahmed A Othman, Vijay V Upreti, Hazem E Hassan, Shariq S Syed, Thomas E Prisinzano, Natalie D Eddington.   

Abstract

Salvinorin A is an unregulated potent hallucinogen isolated from the leaves of Salvia divinorum. It is the only known non-nitrogenous kappa-opioid selective agonist, and rivals synthetic lysergic acid diethylamide (LSD) in potency. The objective of this study was to characterize the in vitro transport, in vitro metabolism, and pharmacokinetic properties of Salvinorin A. The transport characteristics of Salvinorin A were assessed using MDCK-MDR1 cell monolayers. The P-glycoprotein (P-gp) affinity status was assessed by the P-gp ATPase assay. In vitro metabolism studies were performed with various specific human CYP450 isoforms and UGT2B7 to assess the metabolic characteristics of Salvinorin A. Cohorts (n = 3) of male Sprague Dawley rats were used to evaluate the pharmacokinetics and brain distribution of Salvinorin A (10 mg/kg, intraperitoneal (i.p.) over a 240-min period. A validated UV-HPLC and LC/MS/MS method was used to quantify the hallucinogen concentrations obtained from the in vitro and in vivo studies, respectively. Salvinorin A displayed a high secretory transport in the MDCK-MDR1 cells (4.07 +/- 1.34 x 10(-)5 cm/s). Salvinorin A also stimulated the P-gp ATPase activity in a concentration (5 and 10 microM)-dependent manner, suggesting that it may be a substrate of (P-gp). A significant decrease in Salvinorin A concentration ranging from 14.7 +/- 0.80% to 31.1 +/- 1.20% was observed after incubation with CYP2D6, CYP1A1, CYP2C18, and CYP2E1, respectively. A significant decrease was also observed after incubation with UGT2B7. These results suggest that Salvinorin A maybe a substrate of UGT2B7, CYP2D6, CYP1A1, CYP2E1, and CYP2C18. The in vivo pharmacokinetic study showed a relatively fast elimination with a half-life (t1/2) of 75 min and a clearance (Cl/F) of 26 L/h/kg. The distribution was extensive (Vd of 47.1 L/kg); however, the brain to plasma ratio was 0.050. Accordingly, the brain half-life was relatively short, 36 min. Salvinorin A is rapidly eliminated after i.p. dosing, in accordance with its fast onset and short duration of action. Further, it appears to be a substrate for various oxidative enzymes and multi-drug resistant protein, P-gp.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462483      PMCID: PMC2719774          DOI: 10.1016/j.ejpb.2009.01.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  35 in total

1.  Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.

Authors:  K Kreth; K Kovar; M Schwab; U M Zanger
Journal:  Biochem Pharmacol       Date:  2000-06-15       Impact factor: 5.858

2.  Antidepressant effects of the herb Salvia divinorum: a case report.

Authors:  K R Hanes
Journal:  J Clin Psychopharmacol       Date:  2001-12       Impact factor: 3.153

Review 3.  Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

Authors:  Douglas J Sheffler; Bryan L Roth
Journal:  Trends Pharmacol Sci       Date:  2003-03       Impact factor: 14.819

4.  Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants.

Authors:  D S Cox; K R Scott; H Gao; S Raje; N D Eddington
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

5.  Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum.

Authors:  L J Valdés; H M Chang; D C Visger; M Koreeda
Journal:  Org Lett       Date:  2001-11-29       Impact factor: 6.005

6.  Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps.

Authors:  F Peter Guengerich; Grover P Miller; Imad H Hanna; Hideaki Sato; Martha V Martin
Journal:  J Biol Chem       Date:  2002-07-01       Impact factor: 5.157

7.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.

Authors:  Jacob M Hooker; Youwen Xu; Wynne Schiffer; Colleen Shea; Pauline Carter; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-03-15       Impact factor: 6.556

8.  Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Authors:  Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2004-01-08       Impact factor: 4.030

9.  The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Authors:  Eduardo R Butelman; Todd J Harris; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-10-30       Impact factor: 4.530

10.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Authors:  Bryan L Roth; Karen Baner; Richard Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

View more
  17 in total

1.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

2.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

3.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

Review 4.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

5.  The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Authors:  Amy W M Ewald; Peter J Bosch; Aimee Culverhouse; Rachel Saylor Crowley; Benjamin Neuenswander; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Psychopharmacology (Berl)       Date:  2017-05-23       Impact factor: 4.530

Review 6.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

Review 7.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

8.  Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.

Authors:  Michael S Placzek; Genevieve C Van de Bittner; Hsiao-Ying Wey; Scott E Lukas; Jacob M Hooker
Journal:  Neuropsychopharmacology       Date:  2015-06-10       Impact factor: 7.853

9.  Intranasal salvinorin A improves neurological outcome in rhesus monkey ischemic stroke model using autologous blood clot.

Authors:  Longfei Wu; Di Wu; Jian Chen; Chunhua Chen; Tianqi Yao; Xiaoduo He; Yanqin Ma; Xinglong Zhi; Renyu Liu; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-02       Impact factor: 6.200

10.  Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Authors:  Matthew W Johnson; Katherine A MacLean; Michael J Caspers; Thomas E Prisinzano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-02-15       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.